CA2727957A1 - Pharmaceutical composition comprising levamlodipine and indapamide - Google Patents
Pharmaceutical composition comprising levamlodipine and indapamide Download PDFInfo
- Publication number
- CA2727957A1 CA2727957A1 CA2727957A CA2727957A CA2727957A1 CA 2727957 A1 CA2727957 A1 CA 2727957A1 CA 2727957 A CA2727957 A CA 2727957A CA 2727957 A CA2727957 A CA 2727957A CA 2727957 A1 CA2727957 A1 CA 2727957A1
- Authority
- CA
- Canada
- Prior art keywords
- levamlodipine
- indapamide
- pharmaceutical composition
- antihypertensive
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
An antihypertensive pharmaceutical composition is provided, which contains levamlodipine or a pharmaceutically acceptable salt thereof, and indapamide.
In the present invention, levamlodipine and indapamide are administrated in combination for treating hypertension, a good synergistic antihypertensive effect is achieved, and the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone and the side effect of glucose metabolism interference caused when indapamide is administrated alone are mitigated.
In the present invention, levamlodipine and indapamide are administrated in combination for treating hypertension, a good synergistic antihypertensive effect is achieved, and the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone and the side effect of glucose metabolism interference caused when indapamide is administrated alone are mitigated.
Description
ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION
BACKGROUND OF THE INVENTION
Field of Invention The present invention relates to the pharmaceutical field, and more particularly to an antihypertensive pharmaceutical composition.
Related Art In recent years, with the continuous improvement of living standards and the changes in the dietary structure of Chinese people, the increase of life stress, and the increase of the elderly population, the incidence of hypertension is gradually increased, and at the same time, hypertension causes lesions to heart, brain, kidneys, and other organs, is closely related to sugar and lipid metabolism disorders and diabetes, significantly reduces the quality of life of patients, and even threatens the lives of patients in serious cases. A large number of international authoritative clinical studies on hypertension suggest that increased efforts for depressing the blood pressure, and active and sustained depressing of the blood pressure in the hypertension patients below 130/85 mmHg (optimally below 120/80 mmHg) may effectively mitigate lesions of target organs such as heart, brain, and kidneys caused by hypertension, reduce or delay complications such as stroke, coronary heart disease, angina, myocardial infarction, renal failure, atherosclerosis, and aneurysm, reduce the incidence of the cardiovascular events, the mortality, and the morbidity, improve the life quality of the patients, and prolong the life of the patients. According to the global mortality statistics of various diseases of the World Health Organization (WHO), the cardiovascular disease deaths represented by hypertension accounts for 36% of the total number of deaths;
therefore, improving people's awareness on hypertension is of great importance for early-stage prevention and timely treatment.
2008 Consensus of Chinese Experts in Diagnosis and Treatment of Elderly Patients with Hypertension indicates that, treatment through combined administration utilizes multiple different mechanisms for depressing blood pressure, good antihypertensive effect is achieved, adverse reactions are fewer, and thus being more beneficial for protection of target organs. Numerous studies show that, in order to achieve the purpose of positive and intensive blood pressure depression, 70-100% of the patients need to be administrated with two or more antihypertensive drugs in combination. The combined administration can not only significantly improve the antihypertensive effect due to the additive or synergistic effects of the drugs, but also can reduce the side effects of the drugs, and thus the safety and the patient compliance are improved. A
lot of literatures suggest that, due to reasonable combination of two antihypertensive drugs, the adverse effects of the two combined ingredients when administrated separately may also be counteracted. Therefore, when a conventional dose of a single medicine cannot achieve the desired standard effect, it is recommended to adopt a combined administration regimen including compound preparations to treat hypertension patients.
Levamlodipine is an optical pure medicine that is firstly chirally resolved in China, an anti hypertensive medicine that is firstly chirally resolved in the world, and a long-term basic dihydropyridine calcium antagonists, and may be prepared through many methods, see references CN00102701.8 and CN03821593.4. Levamlodipine functions through a site (N site) attached to dihydropyridine on a cell and blocks calcium ions from entering the cardiac and vascular smooth muscle cells in a transmembrane manner, so as to relax the smooth muscle, decrease the vascular resistance, and lower the blood pressure. Presently, clinical trial evidences indicate that, a therapeutic dose of levamlodipine has very slight or no influence on cardiac contractility and atrioventricular conduction, and levamlodipine is a medicine with the minimal effect on sympathetic excitation among the calcium antagonists.
Levamlodipine may also be used to treat hypertension associated with heart failure, reverse ventricular hypertrophy, improve the relaxation function of the heart during the diastolic stage, protect the renal function with mild diuretic function, and prevent coronary heart disease, myocardial infarction, and stroke, and may further partially reverse abnormal circadian rhythm of blood pressure, and have mild anti-platelet effect, anti-myocardial ischemia effect, anti-arrhythmia effect, insulin sensitivity increasing effect and a certain anti-atherosclerosis effect. However, in a blood pressure depressing process, levamlodipine may easily cause sodium and water retention due to the high dosage, thus resulting in edema, so considerable patients withdraw, and the clinical application of levamlodipine is limited.
Indapamide is a non-thiazide diuretic antihypertensive medicine and a sulfonamide derivative, has a half-life of 17 h, and the metabolites thereof still have antihypertensive effect, so indapamide is a diuretic having a certain calcium antagonism. The antihypertensive mechanism of indapamide is complicated and includes that: I']
through the influence on the prostate substances, PG12 (prostaglandin 12) and PGE2 (prostaglandin E2) are increased, and PCF2a (prostaglandin F2a) and TXA2 (thromboxane A2) are decreased, such that the hemorheology is improved, in which PGE2 and PG12 have the function of dilating the coronary artery and peripheral vessels;
:.I through reduction of the response of the vascular wall to sodium ion, the calcium channels of the vascular wall cells are inhibited, and the sodium re-absorption of renal distal tubular is slightly inhibited, to relax the smooth muscle, dilate the vessels, and achieve the effects of diuresis and natriuresis, thus achieving the antihypertensive effects.
The diuretic may mitigate the edema due to sodium and water retention caused by CCB, but indapamide has the side effect of glucose metabolism interference, so use of indapamide at high dose in long term may cause hypokalemia.
SUMMARY OF THE INVENTION
In view of the technical problems existing in depressing the blood pressure in the prior art of the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone and the side effect of glucose metabolism interference caused when indapamide is administrated alone, the present invention is directed to an antihypertensive pharmaceutical composition.
The antihypertensive pharmaceutical composition of the present invention includes levamlodipine or a pharmaceutically acceptable salt thereof, and indapamide.
In the present invention, as levamlodipine and indapamide are administrated in combination, the dosages of levamlodipine and indapamide in the treatment process are reduced, and the same or even better antihypertensive effect is achieved.
Moreover, as levamlodipine and indapamide are administrated at a low dose, the edema side effect due to sodium and water retention caused by levamlodipine and the side effect of glucose metabolism interference caused by indapamide are decreased.
Furthermore, the edema side effect due to sodium and water retention caused by levamlodipine may be further decreased due to the diuretic property of indapamide.
In the present invention, a weight ratio of levamlodipine to indapamide is 1:0.04-1, and preferably 1:0.2-1.
The pharmaceutically acceptable salt is one or more selected from levamlodipine benzenesulfonate, levamlodipine mesylate, levamlodipine acetate, levamlodipine aspartate, levamlodipine tartrate, levamlodipine maleate, levamlodipine sulfate, levamlodipine hydrochloride, and levamlodipine hydrobromide.
The antihypertensive pharmaceutical composition of the present invention further includes a pharmaceutically acceptable adjuvant.
In the antihypertensive pharmaceutical composition of the present invention, a content of levamlodipine is preferably 0.1-30 wt%, more preferably 0.25-5 wt%;
and a content of indapamide is preferably 0.01-5 wt%, and more preferably 0.05-2.5 wt%.
The pharmaceutically acceptable adjuvant is one or more selected from microcrystalline cellulose, pregelatinized starch, lactose, hydroxymethyl starch sodium, magnesium stearate, talc, and polyvinylpyrrolidone (referred to as PVP-k30).
The antihypertensive pharmaceutical composition of the present invention further includes a pharmaceutically acceptable diluent, adhesive, disintegrant, lubricant, coloring agent and/or flavoring agent.
The antihypertensive pharmaceutical composition of the present invention may be prepared into an oral preparation, such as, a tablet or a capsule, in which the tablet may be coated with a sugar coat or a film coat, or be not coated.
The present invention has the following effective and active effects. As levamlodipine and indapamide are administrated in combination, a good synergistic antihypertensive effect is achieved. The dosage of levamlodipine and indapamide is decreased, while the same or even better anti hypertensive effect is achieved.
Moreover, low dose of levamlodipine may also decrease the edema side effect due to sodium and water retention caused by levamlodipine, and the diuretic property of indapamide may further decrease the edema side effect due to sodium and water retention caused by levamlodipine. Furthermore, low dose of indapamide may also decrease the side effect of glucose metabolism interference caused by indapamide.
BRIEF DESCRIPTION OF THE DRAWINGS
No drawings DETAILED DESCRIPTION OF THE INVENTION
Embodiments 1-2 Compound tablets Table I Compositions and doses of compound tablets of Embodiments 1-2 Compositions Embodiment I Embodiment 2 Levarnlodipine 2.5 (based on levamlodipine) 0.2 (based on levamlodipine) benzenesulfonate (g) Indapamide(g) 0.1 0.02 Microcrystalline 30 40 cellulose (g) Pregelatinized starch (g) 77.4 105.78 Lactose (g) 30 40 Hydroxymethyl starch 9 12 sodium (g) Magnesium stearate (g) 1 2 95% ethanol suitable amount suitable amount In total (tablets) 1000 1000 Preparation process: Levamlodipine benzenesulfonate, indapamide, microcrystalline cellulose, pregelatinized starch, lactose, and hydroxymethyl starch sodium were placed in a mortar, and uniformly mixed by grinding, screened with a 20-mesh sieve, added into a suitable amount of 95% ethanol to obtain a soft material, screened with a 20-mesh sieve, granulated, and air dried at 40 C. The dried granules were finished with a 16-mesh sieve, added with magnesium stearate, uniformly mixed and then tableted.
Embodiments 3-4 Compound capsules Table 2 Compositions and doses of compound capsules of Embodiments 3-4 Compositions_ Embodiment 3 Embodiment 4 Levamlodipine 2.5 (based on 60 (based on benzenesulfonate (g) levamlodipine) levamlodipine) Indapamide (g) 2.5 10 Microcrystalline cellulose (g) 135 120 Talc (g) 4 5.4 0.5% solution of PVP-k30 in suitable amount suitable amount ethanol In total (capsules) 1000 1000 Preparation process: levamlodipine benzenesulfonate, indapamide, and microcrystalline cellulose were placed in a mortar, and uniformly mixed by grinding, screened with a 20-mesh sieve, added into a suitable amount of 0.5% solution of PVP-k30 in ethanol to obtain a soft material, screened with a 20-mesh sieve, granulated, and air dried at 40 C. The dried granules were finished with a 16-mesh sieve, added with talc, uniformly mixed, and then capsulated.
Effect Embodiment I Blood pressure depressing test in rats Experiment method: 50 health spontaneous hypertension SHR rats (female to male 1:1, weight 200-240 g) were equally divided into 5 groups according to the level of the hypertension (the specific grouping method is as shown in Table 3), and intragastrically administrated with the medicine. For the blood pressure of the rate, the systolic pressure at the tail artery of the rat when being wake and quite was indirectly measured by an electronic blood pressure meter through the tail volume method respectively before administration and at the end of one, two, three, and four weeks after administration.
Table 3 Grouping of SHR rats Group Number Administrated drug and dose of rats Blank model group 10 Equal volume of 0.9% saline Levamlodipine 10 5 mg levamlodipine benzenesulfonate/kg=d group Indapamide group 10 5 mg indapamide/kg-d Compound 10 2.5 mg levamlodipine benzenesulfonate/kg-d +0.5 mg low-dose group indapamide/kg-d Compound 10 2.5 mg levamlodipine benzenesulfonate/kg=d +2.5 mg high-dose group indapamide/kg-d Note: 2.5 mg levamlodipine benzenesulfonate/kg-d in Table I is calculated based on levamlodipine Experimental results: the levamlodipine group, the indapamide group, the compound low-dose group, the compound high-dose group have significant antihypertensive effect, compared with the blank model group; the compound low-dose group, and the compound high-dose group have significant anti hypertensive effect, compared with the levamlodipine group and the indapamide group. The specific experimental results are as shown in Table 4. In view of the edema side effect, no edema occurred in the blank model group, the indapamide group, the compound low-dose group, and the compound high-dose group, while edema occurred at an incidence rate of 10% in the levamlodipine group.
Table 4 Influence on blood pressure of SHR rats of administration of levamlodipine, indapamide, and compound preparations thereof Group Before I week 2 weeks after 3 weeks after 4 weeks after administrat after administration administration administration ion administrat (KPa) (KPa) (KPa) (KPa) ion (Kpa) Blank 27.09 1.24 27.23 1.11 26.81. 1.25 26.96 1.44 27.14 1.34 model group Levamiodip 26.96 1.29 26.79 1.31 25.33 1.26# 24.55 1.28# 23.87 1.28"
ine group lndapamide 27.02 1.39 26.88 1.38 25.85 1.38# 25.56 1.35" 25.36 1.36#
group Compound 26.72 1.78 26.55 1.82 24.79 1.69"' 23.73 1.56#' 22.68 1.53""
low-dose group Compound 26.79 1.44 26.61 1.45 24.78 1.39#A' 23.67 1.32#A' 22.51 1.14"' high-dose group Note: # compared with the blank model group, p<0.01, = compared with the levamlodipine group, p<0.05, A compared with the levamlodipine group, p<0.01, ^
compared with the indapamide group, p<0.01.
BACKGROUND OF THE INVENTION
Field of Invention The present invention relates to the pharmaceutical field, and more particularly to an antihypertensive pharmaceutical composition.
Related Art In recent years, with the continuous improvement of living standards and the changes in the dietary structure of Chinese people, the increase of life stress, and the increase of the elderly population, the incidence of hypertension is gradually increased, and at the same time, hypertension causes lesions to heart, brain, kidneys, and other organs, is closely related to sugar and lipid metabolism disorders and diabetes, significantly reduces the quality of life of patients, and even threatens the lives of patients in serious cases. A large number of international authoritative clinical studies on hypertension suggest that increased efforts for depressing the blood pressure, and active and sustained depressing of the blood pressure in the hypertension patients below 130/85 mmHg (optimally below 120/80 mmHg) may effectively mitigate lesions of target organs such as heart, brain, and kidneys caused by hypertension, reduce or delay complications such as stroke, coronary heart disease, angina, myocardial infarction, renal failure, atherosclerosis, and aneurysm, reduce the incidence of the cardiovascular events, the mortality, and the morbidity, improve the life quality of the patients, and prolong the life of the patients. According to the global mortality statistics of various diseases of the World Health Organization (WHO), the cardiovascular disease deaths represented by hypertension accounts for 36% of the total number of deaths;
therefore, improving people's awareness on hypertension is of great importance for early-stage prevention and timely treatment.
2008 Consensus of Chinese Experts in Diagnosis and Treatment of Elderly Patients with Hypertension indicates that, treatment through combined administration utilizes multiple different mechanisms for depressing blood pressure, good antihypertensive effect is achieved, adverse reactions are fewer, and thus being more beneficial for protection of target organs. Numerous studies show that, in order to achieve the purpose of positive and intensive blood pressure depression, 70-100% of the patients need to be administrated with two or more antihypertensive drugs in combination. The combined administration can not only significantly improve the antihypertensive effect due to the additive or synergistic effects of the drugs, but also can reduce the side effects of the drugs, and thus the safety and the patient compliance are improved. A
lot of literatures suggest that, due to reasonable combination of two antihypertensive drugs, the adverse effects of the two combined ingredients when administrated separately may also be counteracted. Therefore, when a conventional dose of a single medicine cannot achieve the desired standard effect, it is recommended to adopt a combined administration regimen including compound preparations to treat hypertension patients.
Levamlodipine is an optical pure medicine that is firstly chirally resolved in China, an anti hypertensive medicine that is firstly chirally resolved in the world, and a long-term basic dihydropyridine calcium antagonists, and may be prepared through many methods, see references CN00102701.8 and CN03821593.4. Levamlodipine functions through a site (N site) attached to dihydropyridine on a cell and blocks calcium ions from entering the cardiac and vascular smooth muscle cells in a transmembrane manner, so as to relax the smooth muscle, decrease the vascular resistance, and lower the blood pressure. Presently, clinical trial evidences indicate that, a therapeutic dose of levamlodipine has very slight or no influence on cardiac contractility and atrioventricular conduction, and levamlodipine is a medicine with the minimal effect on sympathetic excitation among the calcium antagonists.
Levamlodipine may also be used to treat hypertension associated with heart failure, reverse ventricular hypertrophy, improve the relaxation function of the heart during the diastolic stage, protect the renal function with mild diuretic function, and prevent coronary heart disease, myocardial infarction, and stroke, and may further partially reverse abnormal circadian rhythm of blood pressure, and have mild anti-platelet effect, anti-myocardial ischemia effect, anti-arrhythmia effect, insulin sensitivity increasing effect and a certain anti-atherosclerosis effect. However, in a blood pressure depressing process, levamlodipine may easily cause sodium and water retention due to the high dosage, thus resulting in edema, so considerable patients withdraw, and the clinical application of levamlodipine is limited.
Indapamide is a non-thiazide diuretic antihypertensive medicine and a sulfonamide derivative, has a half-life of 17 h, and the metabolites thereof still have antihypertensive effect, so indapamide is a diuretic having a certain calcium antagonism. The antihypertensive mechanism of indapamide is complicated and includes that: I']
through the influence on the prostate substances, PG12 (prostaglandin 12) and PGE2 (prostaglandin E2) are increased, and PCF2a (prostaglandin F2a) and TXA2 (thromboxane A2) are decreased, such that the hemorheology is improved, in which PGE2 and PG12 have the function of dilating the coronary artery and peripheral vessels;
:.I through reduction of the response of the vascular wall to sodium ion, the calcium channels of the vascular wall cells are inhibited, and the sodium re-absorption of renal distal tubular is slightly inhibited, to relax the smooth muscle, dilate the vessels, and achieve the effects of diuresis and natriuresis, thus achieving the antihypertensive effects.
The diuretic may mitigate the edema due to sodium and water retention caused by CCB, but indapamide has the side effect of glucose metabolism interference, so use of indapamide at high dose in long term may cause hypokalemia.
SUMMARY OF THE INVENTION
In view of the technical problems existing in depressing the blood pressure in the prior art of the edema side effect due to sodium and water retention caused when levamlodipine is administrated alone and the side effect of glucose metabolism interference caused when indapamide is administrated alone, the present invention is directed to an antihypertensive pharmaceutical composition.
The antihypertensive pharmaceutical composition of the present invention includes levamlodipine or a pharmaceutically acceptable salt thereof, and indapamide.
In the present invention, as levamlodipine and indapamide are administrated in combination, the dosages of levamlodipine and indapamide in the treatment process are reduced, and the same or even better antihypertensive effect is achieved.
Moreover, as levamlodipine and indapamide are administrated at a low dose, the edema side effect due to sodium and water retention caused by levamlodipine and the side effect of glucose metabolism interference caused by indapamide are decreased.
Furthermore, the edema side effect due to sodium and water retention caused by levamlodipine may be further decreased due to the diuretic property of indapamide.
In the present invention, a weight ratio of levamlodipine to indapamide is 1:0.04-1, and preferably 1:0.2-1.
The pharmaceutically acceptable salt is one or more selected from levamlodipine benzenesulfonate, levamlodipine mesylate, levamlodipine acetate, levamlodipine aspartate, levamlodipine tartrate, levamlodipine maleate, levamlodipine sulfate, levamlodipine hydrochloride, and levamlodipine hydrobromide.
The antihypertensive pharmaceutical composition of the present invention further includes a pharmaceutically acceptable adjuvant.
In the antihypertensive pharmaceutical composition of the present invention, a content of levamlodipine is preferably 0.1-30 wt%, more preferably 0.25-5 wt%;
and a content of indapamide is preferably 0.01-5 wt%, and more preferably 0.05-2.5 wt%.
The pharmaceutically acceptable adjuvant is one or more selected from microcrystalline cellulose, pregelatinized starch, lactose, hydroxymethyl starch sodium, magnesium stearate, talc, and polyvinylpyrrolidone (referred to as PVP-k30).
The antihypertensive pharmaceutical composition of the present invention further includes a pharmaceutically acceptable diluent, adhesive, disintegrant, lubricant, coloring agent and/or flavoring agent.
The antihypertensive pharmaceutical composition of the present invention may be prepared into an oral preparation, such as, a tablet or a capsule, in which the tablet may be coated with a sugar coat or a film coat, or be not coated.
The present invention has the following effective and active effects. As levamlodipine and indapamide are administrated in combination, a good synergistic antihypertensive effect is achieved. The dosage of levamlodipine and indapamide is decreased, while the same or even better anti hypertensive effect is achieved.
Moreover, low dose of levamlodipine may also decrease the edema side effect due to sodium and water retention caused by levamlodipine, and the diuretic property of indapamide may further decrease the edema side effect due to sodium and water retention caused by levamlodipine. Furthermore, low dose of indapamide may also decrease the side effect of glucose metabolism interference caused by indapamide.
BRIEF DESCRIPTION OF THE DRAWINGS
No drawings DETAILED DESCRIPTION OF THE INVENTION
Embodiments 1-2 Compound tablets Table I Compositions and doses of compound tablets of Embodiments 1-2 Compositions Embodiment I Embodiment 2 Levarnlodipine 2.5 (based on levamlodipine) 0.2 (based on levamlodipine) benzenesulfonate (g) Indapamide(g) 0.1 0.02 Microcrystalline 30 40 cellulose (g) Pregelatinized starch (g) 77.4 105.78 Lactose (g) 30 40 Hydroxymethyl starch 9 12 sodium (g) Magnesium stearate (g) 1 2 95% ethanol suitable amount suitable amount In total (tablets) 1000 1000 Preparation process: Levamlodipine benzenesulfonate, indapamide, microcrystalline cellulose, pregelatinized starch, lactose, and hydroxymethyl starch sodium were placed in a mortar, and uniformly mixed by grinding, screened with a 20-mesh sieve, added into a suitable amount of 95% ethanol to obtain a soft material, screened with a 20-mesh sieve, granulated, and air dried at 40 C. The dried granules were finished with a 16-mesh sieve, added with magnesium stearate, uniformly mixed and then tableted.
Embodiments 3-4 Compound capsules Table 2 Compositions and doses of compound capsules of Embodiments 3-4 Compositions_ Embodiment 3 Embodiment 4 Levamlodipine 2.5 (based on 60 (based on benzenesulfonate (g) levamlodipine) levamlodipine) Indapamide (g) 2.5 10 Microcrystalline cellulose (g) 135 120 Talc (g) 4 5.4 0.5% solution of PVP-k30 in suitable amount suitable amount ethanol In total (capsules) 1000 1000 Preparation process: levamlodipine benzenesulfonate, indapamide, and microcrystalline cellulose were placed in a mortar, and uniformly mixed by grinding, screened with a 20-mesh sieve, added into a suitable amount of 0.5% solution of PVP-k30 in ethanol to obtain a soft material, screened with a 20-mesh sieve, granulated, and air dried at 40 C. The dried granules were finished with a 16-mesh sieve, added with talc, uniformly mixed, and then capsulated.
Effect Embodiment I Blood pressure depressing test in rats Experiment method: 50 health spontaneous hypertension SHR rats (female to male 1:1, weight 200-240 g) were equally divided into 5 groups according to the level of the hypertension (the specific grouping method is as shown in Table 3), and intragastrically administrated with the medicine. For the blood pressure of the rate, the systolic pressure at the tail artery of the rat when being wake and quite was indirectly measured by an electronic blood pressure meter through the tail volume method respectively before administration and at the end of one, two, three, and four weeks after administration.
Table 3 Grouping of SHR rats Group Number Administrated drug and dose of rats Blank model group 10 Equal volume of 0.9% saline Levamlodipine 10 5 mg levamlodipine benzenesulfonate/kg=d group Indapamide group 10 5 mg indapamide/kg-d Compound 10 2.5 mg levamlodipine benzenesulfonate/kg-d +0.5 mg low-dose group indapamide/kg-d Compound 10 2.5 mg levamlodipine benzenesulfonate/kg=d +2.5 mg high-dose group indapamide/kg-d Note: 2.5 mg levamlodipine benzenesulfonate/kg-d in Table I is calculated based on levamlodipine Experimental results: the levamlodipine group, the indapamide group, the compound low-dose group, the compound high-dose group have significant antihypertensive effect, compared with the blank model group; the compound low-dose group, and the compound high-dose group have significant anti hypertensive effect, compared with the levamlodipine group and the indapamide group. The specific experimental results are as shown in Table 4. In view of the edema side effect, no edema occurred in the blank model group, the indapamide group, the compound low-dose group, and the compound high-dose group, while edema occurred at an incidence rate of 10% in the levamlodipine group.
Table 4 Influence on blood pressure of SHR rats of administration of levamlodipine, indapamide, and compound preparations thereof Group Before I week 2 weeks after 3 weeks after 4 weeks after administrat after administration administration administration ion administrat (KPa) (KPa) (KPa) (KPa) ion (Kpa) Blank 27.09 1.24 27.23 1.11 26.81. 1.25 26.96 1.44 27.14 1.34 model group Levamiodip 26.96 1.29 26.79 1.31 25.33 1.26# 24.55 1.28# 23.87 1.28"
ine group lndapamide 27.02 1.39 26.88 1.38 25.85 1.38# 25.56 1.35" 25.36 1.36#
group Compound 26.72 1.78 26.55 1.82 24.79 1.69"' 23.73 1.56#' 22.68 1.53""
low-dose group Compound 26.79 1.44 26.61 1.45 24.78 1.39#A' 23.67 1.32#A' 22.51 1.14"' high-dose group Note: # compared with the blank model group, p<0.01, = compared with the levamlodipine group, p<0.05, A compared with the levamlodipine group, p<0.01, ^
compared with the indapamide group, p<0.01.
Conclusions: the compound preparations of levamlodipine and indapamide have a better antihypertensive effect than levamlodipine and indapamide, and there is significantly difference in the anti-hypertensive effects. The combined administration of levamlodipine and indapamide has a certain synergistic effect on the spontaneous hypertension rats, and has a therapeutic effect superior to those of the two medicines administrated alone, and the combined administration does not induce the edema side effect due to sodium and water retention.
Claims (10)
1. An antihypertensive pharmaceutical composition, comprising levamlodipine or a pharmaceutically acceptable salt thereof, and indapamide.
2. The antihypertensive pharmaceutical composition according to claim 1, wherein a weight ratio of levamlodipine and indapamide is 1:0.04-1.
3. The antihypertensive pharmaceutical composition according to claim 2, wherein the weight ratio of levamlodipine and indapamide is 1:0.2-1.
4. The anti hypertensive pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt is one or more selected from levamlodipine benzenesulfonate, levamlodipine mesylate, levamlodipine acetate, levamlodipine aspartate, levamlodipine tartrate, levamlodipine maleate, levamlodipine sulfate, levamlodipine hydrochloride, and levamlodipine hydrobromide.
5. The antihypertensive pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable adjuvant.
6. The antihypertensive pharmaceutical composition according to claim 5, wherein a content of levamlodipine is 0.1-30 wt%, and a content of indapamide is 0.01-5 wt%.
7. The antihypertensive pharmaceutical composition according to claim 6, wherein the content of levamlodipine is 0.25-5 wt%, and the content of indapamide is 0.05-2.5 wt%.
8. The antihypertensive pharmaceutical composition according to claim 5, wherein the pharmaceutically acceptable adjuvant is one or more selected from microcrystalline cellulose, pregelatinized starch, lactose, hydroxymethyl starch sodium, magnesium stearate, talc, and polyvinylpyrrolidone.
9. The antihypertensive pharmaceutical composition according to claim 5, further comprising a pharmaceutically acceptable diluent, adhesive, disintegrant, lubricant, coloring agent and/or flavoring agent.
10. The antihypertensive pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a tablet or a capsule
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101582213A CN101804055B (en) | 2010-04-27 | 2010-04-27 | Compound medicinal preparation |
| CN201010158221.3 | 2010-04-27 | ||
| PCT/CN2010/073998 WO2011097857A1 (en) | 2010-02-09 | 2010-06-17 | Antihypertensive pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2727957A1 true CA2727957A1 (en) | 2011-10-27 |
Family
ID=42606115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2727957A Abandoned CA2727957A1 (en) | 2010-04-27 | 2010-06-17 | Pharmaceutical composition comprising levamlodipine and indapamide |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101804055B (en) |
| CA (1) | CA2727957A1 (en) |
| WO (1) | WO2011134191A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102225083B (en) * | 2011-06-20 | 2013-01-16 | 施慧达药业集团(吉林)有限公司 | Pharmaceutical composition for treating hypertension and hyperlipidemia, and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU744982B2 (en) * | 1997-08-29 | 2002-03-07 | Pfizer Products Inc. | Combination therapy comprising amlodipine and a statin compound |
| CN1857726A (en) * | 2005-04-30 | 2006-11-08 | 石家庄制药集团欧意药业有限公司 | Medicine composition for treating hypertension complicated with hyperlipemia and cardiac and cerebral vascular diseases |
| MX2007008440A (en) * | 2007-07-11 | 2009-02-18 | Senosiain S A De C V Lab | Combined pharmaceutical composition. |
| CN101637609A (en) * | 2009-09-06 | 2010-02-03 | 王丽燕 | Drug composition containing amlodipine, A II receptor antagonist and statins |
-
2010
- 2010-04-27 CN CN2010101582213A patent/CN101804055B/en not_active Expired - Fee Related
- 2010-06-17 CA CA2727957A patent/CA2727957A1/en not_active Abandoned
- 2010-06-21 WO PCT/CN2010/074146 patent/WO2011134191A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN101804055A (en) | 2010-08-18 |
| CN101804055B (en) | 2012-01-25 |
| WO2011134191A1 (en) | 2011-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347427A (en) | Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt | |
| CN100364532C (en) | Composition containing amlodipine and angiotensin II receptor inhibitor | |
| KR20100008356A (en) | Pharmaceutical formulation comprising channel blockers | |
| AU2011339150B2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
| WO2013152641A1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| AU2010276461B2 (en) | Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta receptor blocking agent, and use thereof | |
| US8470363B2 (en) | Antihypertensive pharmaceutical composition | |
| CN102370965A (en) | Pharmaceutical composition containing pharmaceutically acceptable salts of levoamlodipine and pharmaceutically acceptable salts of perindopril | |
| CA2727957A1 (en) | Pharmaceutical composition comprising levamlodipine and indapamide | |
| CN102058591A (en) | Levamlodipine and telmisartan compound preparation | |
| EP2374457B1 (en) | Antihypertensive pharmaceutical composition | |
| CN102309480B (en) | Compound antihypertensive pharmaceutical composition and preparation method thereof | |
| CN102327263B (en) | Compound medicinal composition for reducing blood pressure, and compound tablet for reducing blood pressure | |
| WO2009143662A1 (en) | Pharmaceutical composition comprising calcium blocker and b family vitamins and the use thereof | |
| TW200920371A (en) | A combination treatment | |
| CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition | |
| US20190076362A1 (en) | Treatments and Formulations Comprising Torsemide | |
| US10154963B2 (en) | Controlled-release formulations comprising Torsemide | |
| CN101869562B (en) | Levamlodipine compound medicinal preparation | |
| EP2543373A1 (en) | Compound pharmaceutical composition of levoamlodipine | |
| CN201668750U (en) | Compound amlodipine, valsartan and hydrochlorothiazide capsule | |
| CN101766610A (en) | Amlodipine and eprosartan mesylate compound preparation | |
| SULTANA | Karnataka, Bangalore | |
| CN105106962A (en) | Compound antihypertensive preparation and application thereof | |
| KR20090090748A (en) | A preventing and treating agent of blood-vessel related diseases comprising combination drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150617 |